prikaz prve stranice dokumenta COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?
  Download
PDF 367.65 KB
Scientific paper - Original scientific paper
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?
American Journal of Physiology-Heart and Circulatory Physiology, 319 (2020), 4; H793-H796. https://doi.org/10.1152/ajpheart.00506.2020
Jakovac, Hrvoje

Linked objects
COVID-19 | Virtual collection
Cite this document

Jakovac, H. (2020). COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?. American Journal of Physiology-Heart and Circulatory Physiology, 319. (4), H793-H796. doi: 10.1152/ajpheart.00506.2020

Jakovac, Hrvoje. "COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?." American Journal of Physiology-Heart and Circulatory Physiology, vol. 319, no. 4, 2020, pp. H793-H796. https://doi.org/10.1152/ajpheart.00506.2020

Jakovac, Hrvoje. "COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?." American Journal of Physiology-Heart and Circulatory Physiology 319, no. 4 (2020): H793-H796. https://doi.org/10.1152/ajpheart.00506.2020

Jakovac, H. (2020) 'COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?', American Journal of Physiology-Heart and Circulatory Physiology, 319(4), pp. H793-H796. doi: 10.1152/ajpheart.00506.2020

Jakovac H. COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?. American Journal of Physiology-Heart and Circulatory Physiology [Internet]. 2020 October 01 [cited 2024 November 05];319(4):H793-H796. doi: 10.1152/ajpheart.00506.2020

H. Jakovac, "COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?", American Journal of Physiology-Heart and Circulatory Physiology, vol. 319, no. 4, pp. H793-H796, October 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:933914. [Accessed: 05 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?
AuthorHrvoje Jakovac
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Physiology, Immunology and Pathophxsiology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Basic Medical Sciences
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Infectology
Abstract (english)
The 60-kDa heat shock protein (HSP60) is a chaperone essential for mitochondrial proteostasis ensuring thus sufficient aerobic energy production. In pathological conditions, HSP60 can be translocated from the mitochondria and excreted from the cell. In turn, the extracellular HSP60 has a strong ability to trigger and enhance inflammatory response with marked proinflammatory cytokine induction, which is mainly mediated by Toll-like receptor binding. Previous studies have found increased circulating levels of HSP60 in hypertensive patients, as well as enhanced HSP60 expression and membrane translocation in the hypertrophic myocardium. These observations are of particular interest, since they could provide a possible pathophysiological explanation of the severe course and worse outcome of severe acute respiratory syndrome coronavirus 2 infection in hypertensive patients, repeatedly reported during the recent coronavirus disease 2019 (COVID-19) pandemic and related to hyperinflammatory response and cytokine storm development during the third phase of the disease. In this regard, pharmacological inhibition of HSP60 could attract attention to potentially ameliorate inappropriate inflammatory reaction in severe COVID-19 patients. Among HSP60 antagonizing drugs, mizoribine is the most intriguing, since it is clinically approved and exerts antiviral activity. However, this topic requires to be further scrutinized.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleAmerican Journal of Physiology-Heart and Circulatory Physiology
Numberingvol. 319, no. 4, pp. H793-H796
p-ISSN0363-6135
e-ISSN1522-1539
DOIhttps://doi.org/10.1152/ajpheart.00506.2020
URN:NBNurn:nbn:hr:184:933914
Publication2020-10-01
Document URLhttps://journals.physiology.org/doi/10.1152/ajpheart.00506.2020
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2020-09-28 16:18:06